ArticleRadiology and oncology2023
Longitudinal monitoring of Apparent Diffusion Coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-Linac at 1.5 T: a prospective feasibility study.
Article in Radiology and oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Trial
- AI-based detection of temporal changes in MR-Linac images acquired during routine prostate radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.NMR in biomedicine · 2026Article
- The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.Physics in medicine and biology · 2026Review
- MRI-Derived Biomarkers and Radiomic Signatures for Early, Dose-Dependent Evaluation of Prostate Cancer Radiotherapy: An Exploratory Study.Journal of imaging · 2026Article
- Diffusion-weighted imaging-derived parameters as quantitative imaging biomarkers in magnetic resonance-guided radiotherapy: a systematic review.Physics and imaging in radiation oncology · 2025Review
- Radiologists and treatment response assessment: conventional and functional radiological criteria for predicting therapeutic response in virus-related and non-virus-related cancers.Infectious agents and cancer · 2025Review
- Development of in-house software to process real-time cine magnetic resonance images acquired during 1.5 T MR-guided radiation therapy.Scientific reports · 2025Article
- Anatomical zone and tissue type impacts the repeatability of quantitative MRI parameters and radiomic features for longitudinal monitoring of treatment response in the prostate.Magma (New York, N.Y.) · 2025Article
- Online Radiotherapy: The Paradigm Shift to Real-Time Adaptive Radiotherapy.Deutsches Arzteblatt international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHybrid MRI linear accelerators (MR-Linac) might enable individualized online adaptation of radiotherapy using quantitative MRI sequences as diffusion-weighted imaging (DWI). The purpose of this study was to investigate the dynamics of lesion apparent diffusion coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiation therapy (MRgRT) on a 1.5T MR-Linac. The ADC values at a diagnostic 3T MRI scanner were used as the reference standard. PATIENTS AND AND
methodsIn this prospective single-center study, patients with biopsy-confirmed prostate cancer who underwent both an MRI exam at a 3T scanner (MRI
resultsA total of nine male patients aged 67 ± 6 years [range 60 - 67 years] were included. In seven patients, the cancerous lesion was in the peripheral zone, and in two patients the lesion was in the transition zone. Inter-reader reliability regarding lesion ADC measurement was excellent with an intraclass correlation coefficient of (ICC) > 0.90 both at baseline and during radiotherapy. Thus, the results of the first reader will be reported. In both systems, there was a statistically significant elevation of lesion ADC during radiotherapy (mean MRL-ADC at baseline was 0.97 ± 0.18 × 10
conclusionsLesion ADC as measured on MRL increased significantly during radiotherapy and ADC measurements of lesions on both systems showed similar dynamics. This indicates that lesion ADC as measured on the MRL may be used as a biomarker for evaluation of treatment response. In contrast, absolute ADC values as calculated by the algorithm of the manufacturer of the MRL showed systematic deviations from values obtained on a diagnostic 3T MRI system. These preliminary findings are promising but need large-scale validation. Once validated, lesion ADC on MRL might be used for real-time assessment of tumor response in patients with prostate cancer undergoing MR-guided radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.